Literature DB >> 9585159

A new approach to the development of anti-ischemic drugs: protective drugs against cell injury induced by lysophosphatidylcholine.

H Hashizume1, M Chen, H Ma, A Hara, K Yazawa, M Akahira, C Y Xiao, Y Abiko.   

Abstract

Recent studies have revealed that lysophosphatidylcholine (LPC) produces mechanical and metabolic derangements in perfused working rat hearts and Ca2+-overload in isolated cardiac myocytes. Thus, LPC possesses an ischemia-like effect on the heart. Therefore, a drug that possesses an anti-LPC action would protect or improve ischemia/reperfusion damage. We examined the effects of various anti-ischemic drugs on the Ca2+ overload induced by LPC. Our data suggest that a drug with high lipophilicity possesses a protective effect on cell injury induced by LPC, probably because of preservation of membrane integrity.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9585159     DOI: 10.1016/s0024-3205(98)00130-1

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  2 in total

1.  Lysophosphatidylcholine-induced myocardial damage is inhibited by pretreatment with poloxamer 188 in isolated rat heart.

Authors:  Makino Watanabe; Takao Okada
Journal:  Mol Cell Biochem       Date:  2003-06       Impact factor: 3.396

2.  Baicalein, an active component of Scutellaria baicalensis Georgi, prevents lysophosphatidylcholine-induced cardiac injury by reducing reactive oxygen species production, calcium overload and apoptosis via MAPK pathways.

Authors:  Huai-Min Chen; Jong-Hau Hsu; Shu-Fen Liou; Tsan-Ju Chen; Li-Ying Chen; Chaw-Chi Chiu; Jwu-Lai Yeh
Journal:  BMC Complement Altern Med       Date:  2014-07-09       Impact factor: 3.659

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.